BRUSSELS: MDxHealth SA today announced its third quarter 2015 Business Update for the period ended September 30, 2015.
Dr. Jan Groen, Chief Executive Officer of MDxHealth, commented: “The strategic investments made in our managed care team during the first half of 2015, coupled with the expansion of our sales force shortly after our June capital raise have bolstered both revenue growth and adoption of ConfirmMDx for Prostate Cancer in the U.S. Carrying our strong Q3 performance into Q4, we maintain our guidance for the full year.
“With the acquisition of NovioGendix and continued development of our existing pipeline this past quarter, we have established a solid foundation for our expanded uro-oncology product offering and the progression of our global commercial strategy. On November 1st, we launched SelectMDx(TM) for Prostate Cancer service testing in the Benelux region and look forward to launching our CE marked SelectMDx kits across Europe and in the U.S. in the beginning of 2016. Additionally, with promising data to date, and ongoing validation studies for our urine-based bladder cancer test, we continue to expand our novel liquid biopsy product pipeline, which we expect to be a key focus of our future commercial portfolio.”
